Funding News - Intellectual and Developmental Disabilities—Outcome Measures for Treatment Trials

Historical Data

The information on this page is for historical and research purposes only.
For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

NINDS invites applications to develop, validate, and/or calibrate informative outcome measures for use in treatment trials for individuals with intellectual and developmental disabilities (IDD). This announcement is made together with 2 other NIH components.

Clinical trials are being designed that seek to alleviate the debilitating medical symptoms associated with IDD, such as Down syndrome, Fragile X syndrome, Rett syndrome, Angelman syndrome, Prader-Willi syndrome, and autism spectrum disorders. There is an urgent need to identify outcome measures that demonstrate treatment benefit for pharmacologic interventions or behavioral trials developed for use in these disorders, particularly in children. This initiative encourages the identification of endpoints for use in clinical trials of IDD therapies.

Potential applicants should contact Dr. Laura Mamounas, program director, Neurogenetics Cluster, NINDS, at 301-496-5745 or mamounal@mail.nih.gov. For more information visit http://grants.nih.gov/grants/guide/pa-files/PAR-11-045.html.